Table 3 Imaging and Clinico-Pathological Factors between Patients with and without Advanced ALN metastases after Neoadjuvant Chemotherapy.

Age, years*

46.2 ± 8.5

48.3 ± 7.9

0.421

Initial clinical T stages

0.230

  T1

13 (13.5%)

0

  T2

60 (62.5%)

8 (66.7%)

  T3

18 (18.8%)

3 (25.0%)

  T4

5 (5.2%)

1 (8.3%)

Initial clinical N stages

0.195

  N0

6 (6.2%)

0

  N1

38 (39.6%)

4 (33.3%)

  N2

40 (41.7%)

5 (41.7%)

  N3

12 (12.5%)

3 (25.0%)

Histologic grade

0.937

  Low to moderate

73 (76.0%)

9 (75.0%)

  High

23 (24.0%)

3 (25.0%)

HR status

0.890

  Negative

38 (39.6%)

5 (41.7%)

  Positive

58 (60.4%)

7 (58.3%)

HER2 status

0.677

  Negative

58 (60.4%)

8 (66.7%)

  Positive

38 (39.6%)

4 (33.3%)

Number of positive ALNs on initial staging MR imaging**

0.015

  <4

52 (54.2%)

2 (16.7%)

  ≥4

44 (45.8%)

10 (83.3%)

Number of positive ALNs on restaging MR imaging**

<0.001

  <2

86 (89.6%)

5 (41.7%)

  ≥2

10 (10.4%)

7 (58.3%)

Short diameter of the largest ALN on initial staging MR imaging

0.295

  ≤ 7.7 mm

26 (27.1%)

5 (41.7%)

  >7.7 mm

70 (72.9%)

7 (58.3%)

Short diameter of the largest ALN on restaging MR imaging

0.007

  ≤7.7 mm

80 (83.3%)

6 (50.0%)

  >7.7 mm

16 (16.7%)

6 (50.0%)

Nodal SUVmax on initial staging PET/CT

0.060

  ≤2.6

34 (35.4%)

1 (8.3%)

  >2.6

62 (64.6%)

11 (91.7%)

Nodal SUVmax on restaging PET/CT

<0.001

  ≤1.1

84 (87.5%)

5 (41.7%)

  >1.1

12 (12.5%)

7 (58.3%)